Globenewswire·2025-10-21 17:30Core Viewpoint - Rosen Law Firm is reminding investors who purchased aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025, of the December 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is December 8, 2025, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The firm has a history of significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Background - The complaint alleges that defendants made misleading statements regarding the efficacy of Efzofitimod, particularly its ability to allow patients to taper steroid usage, leading to investor damages when the truth was revealed [5].